Qube Research & Technologies (QRT)’s iTeos Therapeutics ITOS Stock Holding History

Qube Research & Technologies (QRT)’s Portfolio ITOS Stock Details ITOS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-107,764	Closed	-$643K	–	3751
2025 Q1	$643K	Sell	107,764 -87,189	-45%	-$640K	﹤0.01%	2452
2024 Q4	$1.5M	Buy	194,953 +19,362	+11%	+$166K	﹤0.01%	1998
2024 Q3	$1.79M	Buy	175,591 +136,987	+355%	+$2.09M	﹤0.01%	1796
2024 Q2	$573K	Buy	38,604 +1,298	+3%	+$18.6K	﹤0.01%	2104
2024 Q1	$509K	Sell	37,306 -45,475	-55%	-$495K	﹤0.01%	2521
2023 Q4	$906K	Buy	+82,781	New	+$821K	﹤0.01%	1980
2023 Q3	–	Sell	-16,413	Closed	-$217K	–	4211
2023 Q2	$217K	Buy	+16,413	New	+$234K	﹤0.01%	1753
2022 Q4	–	Sell	-29,242	Closed	-$557K	–	2734
2022 Q3	$557K	Buy	+29,242	New	+$674K	﹤0.01%	1428

Other funds holding ITOS

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

BCM

Boxer Capital Management San Diego, California $762M AUM 1,125.36% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Qube Research & Technologies (QRT)'s ITOS Position: Q2 2025 in Review

Qube Research & Technologies (QRT) sold out of iTeos Therapeutics (ITOS) in Q2 2025, closing a stake of 107,764 shares — an estimated $643K sold.

Qube Research & Technologies (QRT) first reported a position in ITOS in Q3 2022 and held it in 8 quarters. The position peaked at $1.79M in Q3 2024. 136 funds tracked by Wall St. Rank hold ITOS as of Q2 2025.

Qube Research & Technologies (QRT) reported no remaining iTeos Therapeutics position as of Q2 2025 after selling out during the quarter.
Qube Research & Technologies (QRT) sold 107,764 iTeos Therapeutics shares in Q2 2025, an estimated $643K.
Qube Research & Technologies (QRT) first reported a position in iTeos Therapeutics in Q3 2022 and held it in 8 quarters.
Qube Research & Technologies (QRT)'s iTeos Therapeutics position peaked at $1.79M in Q3 2024.
136 funds tracked by Wall St. Rank held iTeos Therapeutics as of Q2 2025.

Based on Qube Research & Technologies (QRT)'s 13F filing for Q2 2025, filed 14 Aug 2025.